Pfizer Corporation

Vertex Pharmaceuticals, Inc.

Pfizer Products Inc.

Michael Aaron Brodney

Christopher Ryan Butler

Lei Zhang

Brian Thomas O'Neill

Bruce Nelsen Rogers

Elizabeth Mary Beck

Jennifer Elizabeth Davoren

Steven Victor O'Neil

Erik Alphie LaChapelle

Michael Eric Green

Christopher John Helal

David Lawrence Firman Gray

Patrick Robert Verhoest

Laura Ann McAllister

Scot Richard Mente

Ivan Viktorovich Efremov

Jaclyn Louise Henderson

Amy Beth Dounay

Chewah Lee

Karen Jean Coffman

Adam Matthew Gilbert

Ales Medek

Yi Shi

Kevin Gagnon

Gabriela Barreiro

Brad D Maxwell

Jingrong Cao

Jon H Come

Suganthini S Nanthakumar

Justin Ian Montgomery

Muna Shrestha

Leslie A Dakin

Timothy J Senter

Damien Webb

Matthew Frank Brown

John Patrick Maxwell

Dennis James Hurley

Kevin Michael Cottrell

Qing Tang

Upul Keerthi Bandarage

Jinwang Xu

Simon Giroux

Adam R Looker

Michael John Boyd

Stefanie Roeper

Ronald Lee Grey, Jr

Stephen Andrew Thomson

Lev Tyler Dewey Fanning

Douglas Scott Johnson

Mac Arthur Johnson, Jr

Peter D Jones

Philippe Marcel Nuhant

Diane M Boucher

Cavan McKeon Bligh

Setu Roday

Rupa Sawant

Rebecca Jane Swett

Veronique Damagnez

Robert Francis Fimognari, Jr

Tiansheng Wang

Steven M Ronkin

Brian Ledford

Chakrapani Subramanyam

John E Cochran

Michael P Clark

Kathy Stavropoulos

Peter Jamison Rose

Haoxuan Wang

Warren A Dorsch

Elaine B Krueger

Qingyi Yang

Kirk Overhoff

Anne Fortier

Olivier Nicolas

Camil Sayegh

Xinjun J Hou

Yuhpyng Liang Chen

Jotham Wadsworth Coe

Gene M Bright

Travis T Wager

Thomas Allen Chappie

Edward F Kleinman

Hardwin O'Dowd

Jeffrey W Raggon

Joseph Scott Warmus

Bethany Lyn Kormos

Yuan Zhang

Martin Youngjin Pettersson

Michael Waldo

Antonia Friederike Stepan

Paul Galatsis

Matthew Richard Reese

Stephane Caron

Michelle Renee Garnsey

Jinshan Michael Chen

Ravi G Kurumbail

Yong Tao

Gregory Wayne Kauffman

Kapildev Kashmirilal Arora

Bishop Wlodecki

The disclosure provides at least one entity chosen from compounds of Formula I, a tautomer thereof, a deuterated derivative of that compound or tautomer, and a pharmaceutically acceptable salt of any of the foregoing, compositions comprising the same, and methods of using the same, including uses in treating APOL1-mediated diseases, including pancreatic cancer, focal segmental glomerulosclerosis (FSGS), and/or non-diabetic kidney disease (NDKD).

Inhibitors of APOL1 and methods of using same

The present invention provides, in part, compounds of Formula I: or an N-oxide thereof, or a pharmaceutically acceptable salt of the compound or the N-oxide, wherein: X, X, R, R, m and n are as described herein; processes for the preparation of; intermediates used in the preparation of; and compositions containing such compounds, N-oxides, or salts, and their uses for treating M4-mediated (or M4-associated) disorders including, e.g., Alzheimer's Disease, Parkinson's Disease, schizophrenia (e.g., its cognitive and negative symptoms), pain, addiction, and a sleep disorder.

Piperazine azaspiro derivatives

The disclosure provides compounds useful for treating alpha-1 antitrypsin deficiency (AATD), according to formula (I): tautomers thereof, pharmaceutically acceptable salts of the compounds, pharmaceutically acceptable salts of the tautomers, deuterated derivatives of the compounds, deuterated derivatives of the tautomers, and deuterated derivatives of the salts, solid forms of those compounds and processes for making those compounds.

Modulators of alpha-1 antitrypsin

The disclosure provides at least one entity chosen from compounds of formula (I), solid state forms of the same, compositions comprising the same, and methods of using the same, including use in treating focal segmental glomerulosclerosis (FSGS) and/or non-diabetic kidney disease (NDKD).

The present invention provides, in part, compounds of Formula I: and pharmaceutically acceptable salts thereof; processes for the preparation of; intermediates used in the preparation of; and compositions containing such compounds or salts, and their uses for treating D1-mediated (or D1-associated) disorders including, e.g., schizophrenia (e.g., its cognitive and negative symptoms), cognitive impairment (e.g., cognitive impairment associated with schizophrenia, AD, PD, or pharmacotherapy therapy), ADHD, impulsivity, compulsive gambling, overeating, autism spectrum disorder, MCI, age-related cognitive decline, dementia, RLS, Parkinson's disease, Huntington's chorea, anxiety, depression, MDD, TRD, bipolar disorder, chronic apathy, anhedonia, chronic fatigue, post-traumatic stress disorder, seasonal affective disorder, social anxiety disorder, post-partum depression, serotonin syndrome, substance abuse and drug dependence, drug abuse relapse, Tourette's syndrome, tardive dyskinesia, drowsiness, excessive daytime sleepiness, cachexia, inattention, sexual dysfunction, migraine, SLE, hyperglycemia, atherosclerosis, dislipidemia, obesity, diabetes, sepsis, post-ischemic tubular necrosis, renal failure, hyponatremia, resistant edema, narcolepsy, hypertension, congestive heart failure, postoperative ocular hypotonia, sleep disorders, and pain.

Heteroaromatic compounds and their use as dopamine D1 ligands

The present invention provides, in part, compounds of Formula I: or an N-oxide thereof, or a pharmaceutically acceptable salt of the compound or the N-oxide, wherein: R, R, L, A, and E are as described herein; processes for the preparation of; intermediates used in the preparation of; and compositions containing such compounds, N-oxides, or salts, and their uses for treating M4-mediated (or M4-associated) disorders including, e.g., Alzheimer's Disease, schizophrenia (e.g., its cognitive and negative symptoms), pain, addiction, and a sleep disorder.

5,7-dihydro-pyrrolo-pyridine derivatives

Novel compounds, compositions, and methods of using and preparing the same, which may be useful for treating alpha-1 antitrypsin deficiency (AATD).

The disclosure provides a compound of Formula (I), including deuterated derivatives, pharmaceutically acceptable salts, and solvates thereof, solid state forms of those compounds, compositions comprising those compounds and solid forms, and methods of using the same, including use in treating focal segmental glomerulosclerosis (FSGS) and/or non-diabetic kidney disease (NDKD). 

The present invention provides, in part, compounds of Formula I: or an N-oxide thereof, or a pharmaceutically acceptable salt of the compound or the N-oxide, wherein: X, X, R, R, m and n are as described herein; processes for the preparation of; intermediates used in the preparation of; and compositions containing such compounds, N-oxides, or salts, and their uses for treating M4-mediated (or M4-associated) disorders including, e.g., Alzheimer's Disease, Parkinson's Disease, schizophrenia (e.g., its cognitive and negative symptoms), pain, addiction, and a sleep disorder. 

The present invention provides novel imidazo[4,5-c]quinoline derivatives of Formula (I), and the pharmaceutically acceptable salts thereof I wherein R, Rand Rare as defined in the specification. The invention is also directed to pharmaceutical compositions comprising the compounds of Formula I and to use of the compounds in the treatment of diseases associated with LRRK2, such as neurodegenerative diseases including Parkinson's disease or Alzheimer's disease, cancer, Crohn's disease or leprosy. 

Imidazo[4,5-C]quinoline derivatives as LRRK2 inhibitors

The present invention provides, in part, compounds of Formula I, or an N-oxide thereof, or a pharmaceutically acceptable salt of the compound or the N-oxide, wherein: (R)a, (R)b, (R)c, L, A, and E are as described herein; processes for the preparation of; intermediates used in the preparation of; and compositions containing such compounds, N-oxides, or salts, and their uses for treating M4-mediated (or M4-associated) disorders including, e.g., Alzheimer's Disease, schizophrenia (e.g., its cognitive and negative symptoms), pain, addiction, and a sleep disorder. 

Dihydro-pyrrolo-pyridine derivatives

The present invention provides, in part, compounds of Formula I: and pharmaceutically acceptable salts thereof; processes for the preparation of; intermediates used in the preparation of; and compositions containing such compounds or salts, and their uses for treating D1-mediated (or D1-associated) disorders including, e.g., schizophrenia (e.g., its cognitive and negative symptoms), cognitive impairment (e.g., cognitive impairment associated with schizophrenia, AD, PD, or pharmacotherapy therapy), Parkinson's disease and chronic apathy.

The present invention provides, in part, heterocyclic spiro compounds of Formula I: and pharmaceutically acceptable salts thereof; processes for the preparation of; intermediates used in the preparation of; and compositions containing such compounds or salts, and their uses for treating MAGL-mediated diseases and disorders including, e.g., pain, an inflammatory disorder, depression, anxiety, Alzheimer's disease, a metabolic disorder, stroke, or cancer.

Heterocyclic spiro compounds as MAGL inhibitors

Growing community of inventors

Newton, MA, United States of America

Michael Aaron Brodney